Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zentalis Pharmaceuticals granted non-qualified stock options to purchase 136,000 shares to four newly hired employees on November 2, 2026, with an exercise price of $1.85 per share. The options vest over four years under the company's 2022 Inducement Plan.